Trial Profile
Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Anterogen
- 23 Aug 2023 Planned End Date changed from 30 Apr 2021 to 31 Dec 2026.
- 23 Aug 2023 Planned primary completion date changed from 31 Mar 2021 to 31 Dec 2026.
- 15 Jun 2017 New trial record